No Detail Found!

Oral Sildenafil use in Neonates with Persistent Pulmonary Hypertension of Newborn.

Author(s)
Ali Shabbir Hussain Department of Pediatrics and Child Health, The Aga khan University Hospital Karachi-Pakistan
Rehan Ali Department of Pediatrics and Child Health, The Aga khan University Hospital Karachi-Pakistan
Shakeel Ahmed Department of Pediatrics and Child Health, The Aga khan University Hospital Karachi-Pakistan
Farah Naz Department of Pediatrics and Child Health, The Aga khan University Hospital Karachi-Pakistan
Anila Haroon Department of Pediatrics and Child Health, The Aga khan University Hospital Karachi-Pakistan
Abstract
Background: The prevalence of PPHN has been estimated at 1.9 per 1000 live births. After the discovery of iNO's, its efficacy and benefit in PPHN is well established. Even in the best of centers equipped with iNo and ECMO the mortality is around 20%. Also, iNO is expensive and difficult to administer and monitor which makes it difficult choice in our part of the world. Furthermore About 40% of patients do not respond or have rebound pulmonary hypertension after discontinuation. Owing to these reasons, other treatment modalities like phosphodiesterase inhibitors such as Sildenafil need to be evaluated. Methods: We report a retrospective case series of eighteen patients with PPHN admitted in NICU and treated with oral sildenafil. Results: Three (17%) babies had mild, 5 (28%) moderate and 10 (55%) severe PPHN based on echocardiography. Sildenafil was started on all patients on a mean of 1.67 days and stopped on mean 12.6 days. Initial fio2 was 100%, which after starting sildenafil decreased gradually to 40% on mean 10 days. Average length of stay in NICU was 13 days. Twelve (67%) patients survived whereas 6 (33%) expired (Figure 2). No improvement in oxygen Index after 36 hours (p<0.05) was the independent predicting risk factor for PPHN related mortality in the expired patients. Conclusion: Oral sildenafil can be a used in conjunction with other treatment modalities for PPHN especially in resource limited settings. However further studies regarding its comparative efficacy need to be done.
Publication Details
Page(s) 677-680
DOI DOI not available
Published Journal: Journal of Ayub Medical College, Volume: 29, Issue: 4, Year: 2017

Request the full text from PASTIC

Keywords
Neonate, Management, Pulmonary hypertension, Neonatal ICU
References
PortaNF,SteinhornRH,,2012,Pulmonary vasodilator therapy in the NICU: inhaled nitric oxide, sildenafil, and other pulmonary vasodilating agents,Clin Perinatol,39,149,64
SimiyuDE,OkelloC,NyakundiEG,TawakalAH,,2006,Sildenafil in management of persistent pulmonary hypertension of the newborn: report of two cases,East Afr Med J,83,337,40
HumbertM,SitbonO,SimonneauG,,2004,Treatment of pulmonary arterial hypertension,N Engl J Med,351,1425,36
,2003,,Pediatr Pulmonol,36,529,35
DeruelleP,GroverTR,AbmanSH,,2005,Pulmonary vascular effects of nitric oxide-cGMP augmentation in a model of chronic pulmonary hypertension in fetal and neonatal sheep,Am J Physiol Lung Cell Mol Physiol,289,L798,806
DhillonR.,,2012,The management of neonatal pulmonary hypertension,Arch Dis Child Fetal Neonatal Ed,97,F223,8
CastilloJ,HerreraR,ConchaE,ValenciaP,TorbatiD,SolizA.,OralSildenafil,,2005,Treatment as an Alternative to Inhaled no Therapy for Persistent Pulmonary Hypertension of the Newborn,Pediatr Res,58,420,
JulianaAE,AbbadFC,,2005,Severe persistent pulmonary hypertension of the newborn in a setting where limited resources exclude the use of inhaled nitric oxide: successful treatment with sildenafil,Eur J Pediatr,164,626,9
MichelakisE,TymchakW,LienD,WebsterL,HashimotoK,Archer S,,2002,Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhalwe nitric oxide,Circulation,105,2398,403
ShahPS,OhlssonA,,2011,8):CD005494.,Cochrane Database Syst Rev,,,
BaqueroH,SolizA,NeiraF,VenegaME,SolaA,,2006,Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blindedstudy,Pediatrics,117,1077,83
AbramsD,Schulze-NeickI,MageeAG,,2000,Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension,Heart,84,E4,
HuddlestonAJ,KnodererCA,MorrisJL,EbenrothES,,2009,Sildenafil for the treatment of pulmonary hypertension in pediatric patients,Pediatr Cardiol,30,871,82
ShekerdemianLS,RavnHB,PennyDJ,,2002,Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension,Am J Respir Crit Care Med,165,1098,102
0

Citations

0

Downloads

136

Views